TABLE 2.
Factors Associated with Anti-Neoplastic Therapy Use during Hospital Admission that included an APCU Stay
| Chemotherapeutic Agents | Hormonal Agents | Targeted Agents | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No Chemo (N=2307) | Chemo (N=297) | P-valuea | No hormones (N=2550) | Hormones (N=54) | P-valuea | No targeted therapy(N=2449) | Targeted therapy(N=155) | P-valuea | |
| Mean age, years (SD) | 58.9 (13.4) | 54.0 (14.9) | <0.001 | 58.3±13.6 | 59.1±13.6 | 0.66 | 58.6±13.6 | 53.8±14.6 | <0.001 |
| Gender | |||||||||
| Female | 1123 (88.2%) | 150 (11.8%) | 0.55 | 1231 (96.7%) | 42 (3.3%) | <0.001 | 1195 (93.9%) | 78 (6.1%) | 0.71 |
| Male | 1184 (89%) | 147 (11%) | 1319 (99.1%) | 12 (0.9%) | 1254 (94.2%) | 77 (5.8%) | |||
| Race | |||||||||
| White | 1543 (88.4%) | 203 (11.6%) | 0.77 | 1712 (98.1%) | 34 (1.9%) | 0.83 | 1646 (94.3%) | 100 (5.7%) | 0.018 |
| Black | 374 (88.6%) | 48 (11.4%) | 413 (97.9%) | 9 (2.1%) | 390 (92.4%) | 32 (7.6%) | |||
| Hispanic | 272 (88.6%) | 35 (11.4%) | 300 (97.7%) | 7 (2.3%) | 297 (96.7%) | 10 (3.3%) | |||
| Others | 118 (91.5%) | 11 (8.5%) | 125 (96.9%) | 4 (3.1%) | 116 (89.9%) | 13 (10.1%) | |||
| Religion | |||||||||
| Christian | 1886 (89.0%) | 233 (11.0%) | 0.27 | 2075 (97.9%) | 44 (2.1%) | 0.28 | 2001 (94.4%) | 118 (5.6%) | 0.21 |
| Non-Christian | 116 (85.9%) | 19 (14.1%) | 134 (99.3%) | 1 (0.7%) | 124 (91.9%) | 11 (8.1%) | |||
| Cancer typesb | |||||||||
| Hematologic | 191 (62.8%) | 113 (37.2%) | <0.001 | 300 (98.7%) | 4 (1.3%) | 0.23 | 250 (82.2%) | 54 (17.8%) | <0.001 |
| Solid tumors | 2116 (92.0%) | 184 (8.0%) | 2250 (97.8%) | 50 (2.2%) | 2199 (95.6%) | 101 (4.4%) | |||
| Dermatologic | 81 (81.8%) | 18 (18.2%) | 99 (100%) | 0 (0%) | 91 (91.9%) | 8 (8.1%) | |||
| Genitourinary | 230 (84.9%) | 41 (15.1%) | 262 (96.7%) | 9 (3.3%) | 256 (94.5%) | 15 (5.5%) | |||
| Primary unknown | 79 (85.9%) | 13 (14.1%) | 90 (97.8%) | 2 (2.2%) | 79 (85.9%) | 13 (14.1%) | |||
| Breast | 180 (87.0%) | 27 (13.0%) | 186 (89.9%) | 21 (10.1%) | 198 (95.7%) | 9 (4.3%) | |||
| Endocrine | 20 (90.9%) | 2 (9.1%) | 22 (100%) | 0 (0%) | 22 (100%) | 0 (0%) | |||
| Gynecologic | 199 (91.7%) | 18 (8.3%) | 207 (95.4%) | 10 (4.6%) | 215 (99.1%) | 2 (0.9%) | |||
| Gastrointestinal | 482 (94.1%) | 30 (5.9%) | 510 (99.6%) | 2 (0.4%) | 498 (97.3%) | 14 (2.7%) | |||
| Head and neck | 148 (95.5%) | 7 (4.5%) | 155 (100%) | 0 (0%) | 148 (95.5%) | 7 (4.5%) | |||
| Respiratory | 572 (96.1%) | 23 (3.9%) | 589 (99%) | 6 (1%) | 555 (93.3%) | 40 (6.7%) | |||
| Sarcoma | 100 (96.2%) | 4 (3.8%) | 104 (100%) | 0 (0%) | 103 (99.0%) | 1 (1.0%) | |||
| CNS | 25 (96.2%) | 1 (3.8%) | 26 (100%) | 0 (0%) | 26 (100%) | 0 (0%) | |||
| Admission type | |||||||||
| PCU only | 720 (97.3%) | 20 (2.7%) | <0.001 | 728 (98.4%) | 12 (1.6%) | 0.31 | 712 (96.2%) | 28 (3.8%) | 0.003 |
| Onc ward/APCU | 1587 (85.1%) | 277 (14.8%) | 1822 (97.7%) | 42 (2.3%) | 1737 (93.2%) | 127 (6.8%) | |||
| Median MDA hospital admission length, days (Q1–Q3) | 7 (11–16) | 18 (11–26) | <0.001 | 11 (8–17) | 13.5 (9–21) | 0.051 | 11 (8–17) | 15 (10–26) | <0.001 |
| Median APCU admission length, days (Q1–Q3) | 7 (4–10) | 7 (4–9) | 0.003 | 7 (4–10) | 7 (5–9) | 1.0 | 7 (4–10) | 6 (4–9) | 0.11 |
APCU: acute palliative care unit; CI: confidence interval; CNS: Central nervous system; MDA: M. D. Anderson Cancer Center; SD: standard deviation
Comparisons were made between patients who received ANT and those who did not receive ANT; the Chi-square test was used for categorical variables; Student t-test for age; and Mann Whitney test was used for median hospital admission and APCU admission length.
Comparisons were made between all solid tumors and hematogical malignancies using the Chi-square test for chemotherapy and targeted agents, and Fisher’s exact test for hormonal agents
Interval between hospital admission and death or last day of followup if alive